Integrated BioPharma (OTCQX:INBP) reported strong financial results for Q3 2025. Revenue increased 6.1% to $13.9 million compared to $13.1 million in Q3 2024. The company's operating income rose to $0.7 million from $0.4 million year-over-year. For the nine-month period, revenue grew 6.9% to $40.2 million, with operating income of $1.4 million compared to a loss of $0.2 million in the previous year. Net income for Q3 2025 reached $0.6 million ($0.02 per share), up from $0.3 million ($0.01 per share) in Q3 2024. The company's Contract Manufacturing Segment showed strong performance, with its two largest customers accounting for 83% of total revenue in the nine-month period, down from 90% in the previous year, indicating successful customer base expansion.
Integrated BioPharma (OTCQX:INBP) ha riportato risultati finanziari solidi per il terzo trimestre del 2025. I ricavi sono aumentati del 6,1% raggiungendo 13,9 milioni di dollari rispetto ai 13,1 milioni del terzo trimestre 2024. L'utile operativo è salito a 0,7 milioni di dollari da 0,4 milioni anno su anno. Nel periodo di nove mesi, i ricavi sono cresciuti del 6,9% raggiungendo 40,2 milioni di dollari, con un utile operativo di 1,4 milioni rispetto a una perdita di 0,2 milioni dell'anno precedente. L'utile netto per il terzo trimestre 2025 ha raggiunto 0,6 milioni di dollari (0,02 dollari per azione), in aumento rispetto a 0,3 milioni (0,01 dollari per azione) nel terzo trimestre 2024. Il segmento di produzione su contratto dell'azienda ha mostrato una forte performance, con i suoi due maggiori clienti che rappresentano l'83% del totale dei ricavi nel periodo di nove mesi, rispetto al 90% dell'anno precedente, segnalando un'espansione riuscita della base clienti.
Integrated BioPharma (OTCQX:INBP) reportó resultados financieros sólidos para el tercer trimestre de 2025. Los ingresos aumentaron un 6,1% alcanzando los 13,9 millones de dólares en comparación con los 13,1 millones del tercer trimestre de 2024. El ingreso operativo subió a 0,7 millones de dólares desde 0,4 millones año tras año. En el período de nueve meses, los ingresos crecieron un 6,9% hasta 40,2 millones de dólares, con un ingreso operativo de 1,4 millones frente a una pérdida de 0,2 millones en el año anterior. El ingreso neto para el tercer trimestre de 2025 alcanzó los 0,6 millones de dólares (0,02 dólares por acción), frente a 0,3 millones (0,01 dólares por acción) en el tercer trimestre de 2024. El segmento de fabricación por contrato de la empresa mostró un desempeño sólido, con sus dos mayores clientes representando el 83% del total de ingresos en el período de nueve meses, frente al 90% del año anterior, lo que indica una exitosa expansión de la base de clientes.
Integrated BioPharma (OTCQX:INBP)는 2025년 3분기에 강력한 재무 실적을 보고했습니다. 수익은 2024년 3분기 1,310만 달러에서 6.1% 증가한 1,390만 달러를 기록했습니다. 회사의 영업이익은 전년 대비 40만 달러에서 70만 달러로 증가했습니다. 9개월 기간 동안 수익은 6.9% 증가한 4,020만 달러였으며, 영업이익은 전년도의 20만 달러 손실에서 140만 달러 이익으로 전환되었습니다. 2025년 3분기 순이익은 60만 달러(주당 0.02달러)로, 2024년 3분기 30만 달러(주당 0.01달러)에서 증가했습니다. 회사의 계약 제조 부문은 강한 실적을 보였으며, 9개월 기간 동안 가장 큰 두 고객이 전체 매출의 83%를 차지해 전년도의 90%에서 감소하여 고객 기반 확장에 성공했음을 나타냅니다.
Integrated BioPharma (OTCQX:INBP) a publié de solides résultats financiers pour le troisième trimestre 2025. Le chiffre d'affaires a augmenté de 6,1 % pour atteindre 13,9 millions de dollars contre 13,1 millions de dollars au troisième trimestre 2024. Le résultat opérationnel est passé à 0,7 million de dollars contre 0,4 million d'une année sur l'autre. Sur la période de neuf mois, le chiffre d'affaires a progressé de 6,9 % pour atteindre 40,2 millions de dollars, avec un résultat opérationnel de 1,4 million contre une perte de 0,2 million l'année précédente. Le bénéfice net pour le troisième trimestre 2025 a atteint 0,6 million de dollars (0,02 dollar par action), en hausse par rapport à 0,3 million (0,01 dollar par action) au troisième trimestre 2024. Le segment de fabrication sous contrat de la société a affiché une performance solide, ses deux plus grands clients représentant 83 % du chiffre d'affaires total sur la période de neuf mois, contre 90 % l'année précédente, ce qui indique une expansion réussie de la base de clients.
Integrated BioPharma (OTCQX:INBP) meldete starke Finanzergebnisse für das dritte Quartal 2025. Der Umsatz stieg um 6,1 % auf 13,9 Millionen US-Dollar im Vergleich zu 13,1 Millionen US-Dollar im dritten Quartal 2024. Das Betriebsergebnis erhöhte sich von 0,4 Millionen auf 0,7 Millionen US-Dollar im Jahresvergleich. Im Neunmonatszeitraum wuchs der Umsatz um 6,9 % auf 40,2 Millionen US-Dollar, mit einem Betriebsergebnis von 1,4 Millionen US-Dollar im Vergleich zu einem Verlust von 0,2 Millionen im Vorjahr. Der Nettogewinn für das dritte Quartal 2025 erreichte 0,6 Millionen US-Dollar (0,02 US-Dollar pro Aktie), gegenüber 0,3 Millionen (0,01 US-Dollar pro Aktie) im dritten Quartal 2024. Das Segment für Auftragsfertigung des Unternehmens zeigte eine starke Leistung, wobei die beiden größten Kunden im Neunmonatszeitraum 83 % des Gesamtumsatzes ausmachten, gegenüber 90 % im Vorjahr, was auf eine erfolgreiche Erweiterung der Kundenbasis hinweist.
Positive
Revenue growth of 6.1% YoY in Q3 2025
Operating income increased to $0.7M from $0.4M YoY
Net income doubled to $0.6M in Q3 2025 from $0.3M in Q3 2024
Successfully expanded customer base, reducing concentration risk from top customers (83% vs 90%)
Turned around nine-month operating loss of $0.2M to $1.4M profit
Negative
High customer concentration with two clients representing 83% of revenue
Relatively modest profit margins with $0.02 EPS
HILLSIDE, NJ / ACCESS Newswire / May 14, 2025 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025.
Revenue for the quarter ended March 31, 2025 was $13.9 million compared to $13.1 million for the quarter ended March 31, 2024, an increase of $0.8 million or 6.1%. The Company had operating income in the quarter ended March 31, 2025 of approximately $0.7 million compared to $0.4 million in the quarter ended March 31, 2024.
Revenue for the nine-month period ended March 31, 2025 was $40.2 million compared to $37.6 million for the nine-month period ended March 31, 2024, an increase of $2.6 million or 6.9%. The Company had operating income for the nine-month period ended March 31, 2025 of approximately $1.4 million and an operating loss of approximately $0.2 million for the nine-month period ended March 31, 2024.
For the quarters ended March 31, 2025 and 2024, the Company had net income of approximately $0.6 million and $0.3 million, respectively. The Company's net income per share of common stock and diluted net income per share of common stock for the quarters ended March 31, 2025 and 2024 were $0.02 and $0.01 per share of common stock, respectively.
For the nine-month periods ended March 31, 2025 and 2024, the Company had net income of approximately $1.0 million and a net loss of approximately $0.2 million, respectively. The Company's net income (loss) per share of common stock and diluted net income (loss) per share of common stock for the nine months ended March 31, 2025 and 2024 were $0.03 and $(0.01), respectively.
"Our revenues increased by 6.9% in the nine months ended March 31, 2025 compared to the comparable period a year ago. Our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 83% and 90% of total revenue in the nine-month period ended March 31, 2025 and 2024, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. "We are happy to report that while focusing on our core business we were able to expand our customer base over the past year and increase our revenue," the Co-CEOs further stated.
A summary of our financial results for the three months and nine months ended March 31, 2025 and 2024 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) (Unaudited)
Three Months Ended
Nine Months Ended
March 31,
March 31,
2025
2024
2025
2024
Total revenue
$
13,947
$
13,147
$
40,178
$
37,571
Cost of sales
12,396
11,899
36,085
34,971
Gross profit
1,551
1,248
4,093
2,600
Selling and administrative expenses
812
893
2,662
2,751
Operating income (loss)
739
355
1,431
(151
)
Other income (expense), net
39
(3
)
36
5
Income (loss) before income taxes
778
352
1,467
(146
)
Income tax expense, net
167
67
481
10
Net income (loss)
$
611
$
285
$
986
$
(156
)
Net income (loss) per share:
Basic
$
0.02
$
0.01
$
0.03
$
(0.01
)
Diluted
$
0.02
$
0.01
$
0.03
$
(0.01
)
Weighted average common shares outstanding:
Basic
30,300,720
30,099,610
30,190,869
30,054,883
Diluted
31,514,591
30,744,222
30,960,916
30,054,883
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
What was Integrated BioPharma's (INBP) revenue in Q3 2025?
Integrated BioPharma reported revenue of $13.9 million in Q3 2025, a 6.1% increase from $13.1 million in Q3 2024.
How much did INBP earn per share in Q3 2025?
INBP earned $0.02 per share in Q3 2025, doubling from $0.01 per share in Q3 2024.
What percentage of INBP's revenue comes from its top customers?
INBP's two largest customers in the Contract Manufacturing Segment represented approximately 83% of total revenue in the nine-month period ended March 31, 2025.
How much operating income did INBP generate in Q3 2025?
INBP generated operating income of $0.7 million in Q3 2025, up from $0.4 million in Q3 2024.
What was INBP's net income for the nine months ended March 31, 2025?
INBP reported net income of $1.0 million for the nine months ended March 31, 2025, compared to a net loss of $0.2 million in the same period of 2024.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
